Krystexxa is a medication used to treat gout and can be effective when other treatments have not produced the desired results.
FDA approval for Krystexxa was granted in 2010.
In 2011 Medicare assigned a treatment code to Krystexxa.
Krystexxa is infusion therapy, covered under Medicare Part B. Due to the cost ($60,000 per year) there may be limits placed on how many treatments will be approved by Medicare.
.JPG){kind=avatar}
FDA approval for Krystexxa was granted in 2010.
In 2011 Medicare assigned a treatment code to Krystexxa.
Krystexxa is infusion therapy, covered under Medicare Part B. Due to the cost ($60,000 per year) there may be limits placed on how many treatments will be approved by Medicare.